Regentatlantic Capital buys $10,622,841 stake in Amgen (AMGN)

Amgen (AMGN) : Regentatlantic Capital scooped up 306 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 18, 2016. The investment management firm now holds a total of 65,071 shares of Amgen which is valued at $10,622,841.Amgen makes up approximately 1.00% of Regentatlantic Capital’s portfolio.

Other Hedge Funds, Including , Leavell Investment Management boosted its stake in AMGN in the latest quarter, The investment management firm added 100 additional shares and now holds a total of 12,410 shares of Amgen which is valued at $2,025,933. Amgen makes up approx 0.29% of Leavell Investment Management’s portfolio.Braver Wealth Management reduced its stake in AMGN by selling 1,094 shares or 3.4% in the most recent quarter. The Hedge Fund company now holds 31,108 shares of AMGN which is valued at $4,993,456. Amgen makes up approx 0.83% of Braver Wealth Management’s portfolio.

Amgen opened for trading at $162.45 and hit $163.65 on the upside on Wednesday, eventually ending the session at $163.25, with a gain of 0.47% or 0.76 points. The heightened volatility saw the trading volume jump to 21,61,425 shares. Company has a market cap of $122,636 M.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *